hot nodule and toxic adenoma in thyroid scan?
Reading File
Finding Sources
Finding Sources
Searching the Web
hot nodule toxic adenoma thyroid scan scintigraphy clinical features
Reading File
Reading File
Reading File
Reading File
Excellent - I have comprehensive information from multiple authoritative textbooks. Here is a full, well-structured answer:
Hot Nodule and Toxic Adenoma on Thyroid Scan
What is a "Hot Nodule"?
A hot nodule is a thyroid nodule that concentrates radiotracer (Tc-99m pertechnetate or I-123) to a far greater degree than the surrounding thyroid tissue on a radionuclide scan. Because TSH is suppressed by autonomous hormone overproduction, the surrounding extranodular tissue shows decreased or absent uptake (partial or complete suppression), making the nodule stand out as a "hot" area.
- Hot nodule = autonomously functioning thyroid nodule (AFTN)
- Also called: hyperfunctioning nodule
- Contrast: a cold nodule shows relative photopenia (reduced/absent uptake) and was historically suspicious for malignancy
"In patients with toxic adenoma the uptake will concentrate at the area with the nodule (a hyperfunctioning or 'hot' nodule), whereas patients with hypofunctioning nodule(s) ('cold' nodule) will demonstrate relative photopenia." - Mulholland and Greenfield's Surgery, p.4030
Toxic Adenoma - Definition
A toxic adenoma is a single autonomously functioning nodule within an otherwise normal or nontoxic thyroid gland that produces excess thyroid hormone independently of TSH stimulation. It is the cause of the classic "hot nodule with suppression of the rest of the gland" pattern on scan.
- Also known as: Plummer's disease (eponym, though some use this for 1-2 hyperfunctioning nodules)
- Also called: autonomously functioning thyroid nodule (AFTN) when not yet causing overt hyperthyroidism
Pathogenesis
The main mechanism is constitutively activating somatic mutations in the TSH receptor (TSH-R) gene, causing the receptor to signal continuously without TSH binding. Less commonly, mutations in the Gs-protein alpha subunit (gsp) also occur. The prevalence of TSH-R mutations varies by geography.
Because the nodule functions autonomously (TSH-independently), it suppresses pituitary TSH via negative feedback, causing the rest of the thyroid gland to become quiescent.
Scan Appearance - Key Patterns
| Scan Finding | Meaning |
|---|---|
| Hot nodule + complete suppression of rest of gland | Classic toxic adenoma - TSH fully suppressed |
| Hot nodule + partial suppression | Toxic adenoma - subclinical hyperthyroidism |
| Multiple hot nodules + suppressed background | Toxic multinodular goiter (TMNG) |
| Diffuse symmetric increased uptake throughout gland | Graves' disease |
| Cold nodule | Hypofunctioning - higher suspicion for malignancy |
The hot nodule of a toxic adenoma shows intense radionuclide uptake with nearly complete absence of uptake in the remainder of the thyroid gland - this is the pathognomonic scan appearance.
"Radionuclide uptake imaging of the thyroid shows intense nuclear uptake in the location of the palpable nodule and nearly complete absence of uptake in the remainder of the thyroid gland." - Cummings Otolaryngology, p. (block 27)
Clinical Features
- Demographics: Primarily females, median age 50-60 years (though can occur at any adult age)
- Presentation: Recent growth of a long-standing nodule + symptoms of hyperthyroidism
- Physical exam: Solitary thyroid nodule, often no palpable contralateral thyroid tissue
- Size: Usually ≥3 cm before overt hyperthyroidism develops (smaller nodules may be subclinical)
- About 20% have overt thyrotoxicosis; another 20% have subclinical thyrotoxicosis at diagnosis
- Toxic adenoma shares most diagnostic/workup approach with toxic multinodular goiter (ATA guidelines combine them for treatment)
Lab Findings
- Suppressed TSH
- Elevated free T4 and/or T3
- No extrathyroidal manifestations (no Graves' ophthalmopathy, no pretibial myxedema)
- Thyroglobulin antibodies usually absent
Malignancy Risk
Hot nodules are rarely malignant - risk is approximately 1-4% (vs. 5-8% for cold nodules). This is an important distinction: a hot nodule on scan effectively argues against malignancy, and FNA is generally not required for hot nodules.
Radiopharmaceuticals Used
| Agent | Notes |
|---|---|
| Tc-99m pertechnetate | Most common; emits gamma radiation; taken up but NOT organified; imaging within 20-30 min of injection |
| I-123 | Oral; images at 4 and 24 hours; allows RAIU measurement |
| I-131 | Longer half-life (~8 days); used for ablative therapy; diagnostic doses 1-5 mCi |
Scintigraphy Use in Hyperthyroidism Workup
Thyroid scintigraphy is most useful in patients with hyperthyroidism to distinguish:
- Toxic adenoma (single hot nodule)
- Toxic multinodular goiter (multiple hot nodules)
- Graves' disease (diffuse symmetric uptake)
Current ETA 2023 guidelines recommend scintigraphy when TSH is subnormal, to diagnose functioning nodules, avoid unnecessary FNA, and guide RAI eligibility.
Treatment
| Modality | Details |
|---|---|
| Antithyroid drugs | Short-term control only; NOT effective for long-term remission; used for preoperative preparation |
| Radioactive iodine (RAI/I-131) | Definitive option; slight-to-moderate risk of hypothyroidism; smaller doses needed than for Graves' |
| Surgery (lobectomy + isthmusectomy) | Preferred for young patients and large nodules (>3 cm); near-universal cure; very low recurrence |
| Percutaneous ethanol injection (PEI) | More common in Europe; requires multiple sessions; suitable for poor surgical candidates |
| Radiofrequency ablation (RFA) | Not recommended as first-line for large toxic adenomas; can be considered for small nodules in young patients |
- Preoperative preparation: 4-6 weeks of antithyroid drugs + 7-10 days of Lugol's iodine before surgery
- Note: SSKI/Lugol NOT indicated for toxic multinodular goiter (risk of Jod-Basedow phenomenon)
- After lobectomy: near-zero recurrence and very low hypothyroidism risk (unlike RAI)
Summary Points (Exam-Focused)
- Hot nodule on scan = autonomously functioning nodule = toxic adenoma (if single nodule with suppressed rest of gland)
- Pathogenesis = constitutive TSH-R mutation → TSH-independent hormone secretion
- Scan: Hot nodule + suppressed background (partial or complete)
- Size threshold: Usually >3 cm before overt hyperthyroidism
- Malignancy risk is very low (<4%) - no FNA needed
- Treatment: RAI or lobectomy for definitive cure; antithyroid drugs only for bridging
- Spontaneous infarction of a nontoxic adenoma can transiently cause thyrotoxicosis (rare)
- Scintigraphy differentiates toxic adenoma vs. TMNG vs. Graves' disease - key clinical utility
Sources: Sabiston Textbook of Surgery; Mulholland & Greenfield's Surgery; Schwartz's Principles of Surgery 11e; Cummings Otolaryngology
This is a shared conversation. Sign in to Orris to start your own chat.